135 related articles for article (PubMed ID: 17660712)
1. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
Giuriato S; Faumont N; Bousquet E; Foisseau M; Bibonne A; Moreau M; Al Saati T; Felsher DW; Delsol G; Meggetto F
Cancer Biol Ther; 2007 Aug; 6(8):1318-23. PubMed ID: 17660712
[TBL] [Abstract][Full Text] [Related]
2. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
Giuriato S; Foisseau M; Dejean E; Felsher DW; Al Saati T; Demur C; Ragab A; Kruczynski A; Schiff C; Delsol G; Meggetto F
Blood; 2010 May; 115(20):4061-70. PubMed ID: 20223922
[TBL] [Abstract][Full Text] [Related]
3. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S
Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
Cheng M; Ott GR
Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
[TBL] [Abstract][Full Text] [Related]
6. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic TPM3-ALK activation requires dimerization through the coiled-coil structure of TPM3.
Amano Y; Ishikawa R; Sakatani T; Ichinose J; Sunohara M; Watanabe K; Kage H; Nakajima J; Nagase T; Ohishi N; Takai D
Biochem Biophys Res Commun; 2015 Feb; 457(3):457-60. PubMed ID: 25596129
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
van der Krogt JA; Bempt MV; Ferreiro JF; Mentens N; Jacobs K; Pluys U; Doms K; Geerdens E; Uyttebroeck A; Pierre P; Michaux L; Devos T; Vandenberghe P; Tousseyn T; Cools J; Wlodarska I
Haematologica; 2017 Sep; 102(9):1605-1616. PubMed ID: 28659337
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
10. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
Turturro F; Arnold MD; Frist AY; Pulford K
Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
[TBL] [Abstract][Full Text] [Related]
11. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
Lawrence B; Perez-Atayde A; Hibbard MK; Rubin BP; Dal Cin P; Pinkus JL; Pinkus GS; Xiao S; Yi ES; Fletcher CD; Fletcher JA
Am J Pathol; 2000 Aug; 157(2):377-84. PubMed ID: 10934142
[TBL] [Abstract][Full Text] [Related]
12. Correlation of seven biological factors (Hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma.
Li HL; Huang XP; Zhou XH; Ji TH; Wu ZQ; Wang ZQ; Jiang HY; Liu FR; Zhao T
Biomed Environ Sci; 2011 Dec; 24(6):630-41. PubMed ID: 22365399
[TBL] [Abstract][Full Text] [Related]
13. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
14. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
J Pharmacol Exp Ther; 2014 Oct; 351(1):67-76. PubMed ID: 25073473
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.
Kruczynski A; Mayer P; Marchand A; Vispé S; Fournier E; Annereau JP; Brel V; Barret JM; Delsol G; Imbert T; Fahy J; Bailly C
Anticancer Drugs; 2009 Jun; 20(5):364-72. PubMed ID: 19322071
[TBL] [Abstract][Full Text] [Related]
16. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
17. New insight into oncoprotein-targeted antitumor effect: herbimycin A as an antagonist of protein tyrosine kinase against Ph1-positive leukemia cells.
Okabe M; Uehara M
Leuk Lymphoma; 1993 Dec; 12(1-2):41-9. PubMed ID: 8161936
[TBL] [Abstract][Full Text] [Related]
18. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.
Mologni L; Ceccon M; Pirola A; Chiriano G; Piazza R; Scapozza L; Gambacorti-Passerini C
Oncotarget; 2015 Mar; 6(8):5720-34. PubMed ID: 25749034
[TBL] [Abstract][Full Text] [Related]
19. Effect of herbimycin A, an inhibitor of tyrosine kinase, on protein tyrosine kinase activity and phosphotyrosyl proteins of Ph1-positive leukemia cells.
Okabe M; Kawamura K; Miyagishima T; Itaya T; Goodwyn D; Shoji M; Vogler WR; Sakurada K; Uehara M; Miyazaki T
Leuk Res; 1994 Mar; 18(3):213-20. PubMed ID: 7511193
[TBL] [Abstract][Full Text] [Related]
20. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.
Piva R; Chiarle R; Manazza AD; Taulli R; Simmons W; Ambrogio C; D'Escamard V; Pellegrino E; Ponzetto C; Palestro G; Inghirami G
Blood; 2006 Jan; 107(2):689-97. PubMed ID: 16189272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]